const axios = require('axios');

const generateAdvancedArticle = () => {
  return {
    title: 'Advanced Flow Cytometry in the Diagnosis of Hematologic Malignancies',
    content: `
      <h2>Abstract</h2>
      <p>Flow cytometry (FCM) has become an indispensable tool in the modern clinical laboratory for the diagnosis, classification, and monitoring of hematologic malignancies. This comprehensive review explores the fundamental principles, advanced multicolor panel design, and interpretation algorithms critical for differentiating neoplastic from reactive hematolymphoid proliferations.</p>
      
      <h2>1. Introduction to Multiparameter Flow Cytometry</h2>
      <p>Historically limited to basic immunophenotyping, contemporary multiparameter FCM now routinely evaluates 8 to 10+ fluorochromes simultaneously. By measuring forward scatter (FSC), side scatter (SSC), and a suite of fluorochrome-conjugated monoclonal antibodies, laboratorians can construct detailed antigenic profiles of individual cells at rates exceeding 10,000 events per second.</p>
      
      <blockquote>"The transition from 4-color to 10-color flow cytometry represents a paradigm shift, enabling the detection of minimal residual disease (MRD) down to 10<sup>-5</sup> sensitivity."</blockquote>
      
      <h2>2. Principles of Panel Design and Fluorochrome Selection</h2>
      <p>Effective panel design requires a deep understanding of antigen density and fluorochrome brightness (stain index). The principles of assigning fluorochromes include:</p>
      <ul>
        <li><strong>Bright Fluorochromes (e.g., PE, APC):</strong> Assigned to dimly expressed antigens or critical lineage markers (e.g., CD34, CD117).</li>
        <li><strong>Dim Fluorochromes (e.g., FITC, Pacific Blue):</strong> Assigned to highly expressed antigens (e.g., CD45, CD3).</li>
        <li><strong>Tandem Dyes (e.g., PE-Cy7, APC-H7):</strong> Used cautiously due to potential degradation and spectral overlap. Proper compensation and fluorescence minus one (FMO) controls are strictly mandated.</li>
      </ul>

      <h2>3. Diagnostic Algorithms in Acute Leukemias</h2>
      <h3>3.1 Acute Myeloid Leukemia (AML)</h3>
      <p>In AML, the leukemic blasts characteristically express immature markers (CD34, CD117, HLA-DR) alongside myeloid antigens (CD13, CD33, MPO). Aberrant antigen expression, such as cross-lineage expression (e.g., CD7 or CD56 on myeloblasts), is highly diagnostic and serves as a critical baseline for subsequent MRD tracking.</p>

      <h3>3.2 B-Lymphoblastic Leukemia (B-ALL)</h3>
      <p>The standard B-ALL profile exhibits CD19, CD10, CD22, and cytoplasmic CD79a. The pattern of CD45 versus SSC typically reveals blasts occupying the "dim CD45" gate. Maturation arrest is often evidenced by the asynchronous co-expression of terminal deoxynucleotidyl transferase (TdT) and mature B-cell markers.</p>

      <h2>4. The Role of Minimal Residual Disease (MRD)</h2>
      <p>MRD detection is arguably the most critical application of advanced FCM in pediatric and adult oncology. Utilizing a <strong>leukemia-associated immunophenotype (LAIP)</strong> or a <strong>different from normal (DfN)</strong> approach, laboratories can detect residual disease that morphological examination would miss.</p>
      
      <div style="background: #f8fafc; padding: 1rem; border-left: 4px solid #1f4e70; margin: 2rem 0;">
        <h4 style="margin-top:0;">Standardized MRD Protocol Highlights</h4>
        <ol>
          <li>Acquisition of a minimum of 1,000,000 events.</li>
          <li>Rigorous exclusion of doublets and non-viable cells (e.g., using 7-AAD or DAPI).</li>
          <li>Identification of normal B-cell precursors (hematogones) to prevent false-positive B-ALL MRD reporting.</li>
        </ol>
      </div>

      <h2>5. Quality Assurance and Standardization (EuroFlow Consortium)</h2>
      <p>The EuroFlow Consortium has standardized instrument settings, panel designs, and sample preparation protocols. Adherence to EuroFlow guidelines ensures intra- and inter-laboratory reproducibility, which is paramount in multi-center clinical trials. Daily quality control utilizing standardized calibration beads is non-negotiable.</p>

      <h2>Conclusion</h2>
      <p>The clinical utility of flow cytometry in hematopathology continues to expand. As we move towards mass cytometry (CyTOF) and spectral flow cytometry capable of analyzing 40+ parameters, the complexity of data interpretation will require integrated computational tools and artificial intelligence to assist the modern medical laboratory scientist.</p>
    `,
    category: 'Hematology',
    status: 'published',
    tags: ['flow-cytometry', 'hematology', 'leukemia', 'clinical-pathology', 'MRD'],
    coverImage: 'https://images.unsplash.com/photo-1579154204601-01588f351e67?auto=format&fit=crop&q=80&w=1600' // Scientific microscope/lab image
  };
};

const seed = async () => {
  const article = generateAdvancedArticle();
  
  try {
    const res = await axios.post('http://localhost:4000/api/v1/articles', article);
    console.log('Successfully seeded advanced article!');
    console.log('Title:', res.data.title);
    console.log('ID:', res.data._id);
  } catch (err) {
    console.error('Failed to seed article:', err.message);
  }
};

seed();
